Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases.
Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases.
复制标题
DOI：
10.1016/j.addr.2013.07.020
复制
发表时间：
2013-11
影响因子：
16.1
通讯作者：
Sarmento B
中科院分区：
文献类型：
--
作者：
Andrade F;Rafael D;Videira M;Ferreira D;Sosnik A;Sarmento B
自古以来，肺和气道就被特别用于肺部疾病的局部治疗，是局部和全身药物给药的多功能靶向途径。尽管存在用于肺部给药的不同平台和装置，但只有少数制剂上市，部分原因是生理和技术限制。呼吸道感染是全世界卫生系统的一个重大负担，主要是由于院内感染更容易影响免疫受损的患者。此外，结核病（TB）是许多发展中国家的地方性传染病，并且在发达国家与人体免疫缺陷病毒/获得性免疫缺陷综合症（HIV/AIDS）流行病相关地重新流行。目前，医学面临着抗生素耐药性的幽灵。除了开发新的抗感染药物外，开发创新和更有效的药物输送系统似乎是制药业追求的一项有前途的战略，以改善治疗效果并延长其知识产权组合的效用。在这种情况下，纳米技术为基础的药物输送系统（纳米DDS）出现作为一个有前途的方法，以规避传统配方的局限性，并治疗耐药性，在这一领域的新发展的假设。
Used since ancient times especially for the local treatment of pulmonary diseases, lungs and airways are a versatile target route for the administration of both local and systemic drugs. Despite the existence of different platforms and devices for the pulmonary administration of drugs, only a few formulations are marketed, partly due to physiological and technological limitations. Respiratory infections represent a significant burden to health systems worldwide mainly due to intrahospital infections that more easily affect immune-compromised patients. Moreover, tuberculosis (TB) is an endemic infectious disease in many developing nations and it has resurged in the developed world associated with the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic. Currently, medicine faces the specter of antibiotic resistance. Besides the development of new anti-infectious drugs, the development of innovative and more efficient delivery systems for drugs that went off patent appears as a promising strategy pursued by the pharmaceutical industry to improve the therapeutic outcomes and to prolong the utilities of their intellectual property portfolio. In this context, nanotechnology-based drug delivery systems (nano-DDS) emerged as a promising approach to circumvent the limitations of conventional formulations and to treat drug resistance, opening the hypothesis for new developments in this area.
登录
查看更多内容
影响因子：
5.8
作者：
Alipour, Misagh;Halwani, Majed;Suntres, Zacharias E.
通讯作者：
Suntres, Zacharias E.
影响因子：
13.3
作者：
Bailey, Mark M.;Berkland, Cory J.
通讯作者：
Berkland, Cory J.
影响因子：
4.5
作者：
Agrawal, AK;Agrawal, A;Gupta, CM
通讯作者：
Gupta, CM
影响因子：
3.4
作者：
Alexander, Barbara D.;Winkler, Thomas P.;Hickey, Anthony J.
通讯作者：
Hickey, Anthony J.
影响因子：
3.3
作者：
Abdulla, Juma Masoud Abdulla;Tan, Yvonne Tze-Fung;Darwis, Yusrida
通讯作者：
Darwis, Yusrida